(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On November 30, 2017, KEI has received a response from the National Institute of Allergy and Infectious Diseases regarding our previous joint comments with MSFon the proposed exclusive… Continue Reading
The Managers Amendment for the “Tax Cuts and Jobs Act” is available on the Senate Finance web page here: https://www.finance.senate.gov/imo/media/doc/11.20.17%20Tax%20Cuts%20and%20Jobs%20Act.pdf I was looking over the Orphan Drug Tax Credit (ODTC) language. The earlier Senate Finance proposal was a more complex… Continue Reading
On November 17, 2017, KEI provided comments in KEI-FDA-2017-N-3615 These were the topics discussed: Transparency Clinical trial costs Data from the Orphan Drug program Costs of trials for government funded research Asset acquisition costs. Licensing Access to Knowhow, data and materials… Continue Reading
On Monday, 27 November 2017, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public health, innovation and intellectual property (EB142/14). The full report of the overall programme review (OPR)… Continue Reading
Meeting: EB Special session on the draft Thirteenth General Programme of Work Agenda Item: 3. Draft Thirteenth General Programme of Work Statement: KEI welcomes the opportunity to comment on the 13th General Programme of Work anchored upon WHO’s vision of… Continue Reading
From November 21 to 23, the Government of India and the World Health Organization are hosting the “1st World Conference on Access to Medical Products and International Laws for Trade and Health, in the Context of the 2030 Agenda for… Continue Reading
November 15, 2017. . Copyright: WIPO. Photo: Emmanuel Berrod. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO License. After discussing the Broadcasters, cablecasters and webcasters treaty also called by some the “youtube” Treaty, the Committtee moved on… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Background: The National Institutes of Health has proposed giving an exclusive license for multiple Zika vaccine candidates to PaxVax, a company with close ties to the federal… Continue Reading
Day 1 at WIPO STANDING COMMITTEE ON COPYRIGHT AND RELATED RIGHTS Since 1998, the WIPO Standing Committee on Copyright and Related Rights (SCCR),has engaged in negotiations to create new norms for the protection of broadcasters, cablecasters and now –again– webcasters… Continue Reading
Statement by James Love, KEI Director, on GOP proposal to eliminate the Orphan Drug Tax Credit.
The GOP proposal to eliminate the Orphan Drug Tax Credit may create a new opportunity to reform the incentives for rare diseases, even if the tax bill fails or the tax credit survives. The GOP tax bill shows there is weaker support for the existing regime than many thought.